Skip to main content

STRATA Skin Sciences, Inc.

corporate_fare Company Profile

STRATA Skin Sciences, Inc.

SSKN·OTC·Healthcare·CIK 0001051514

STRATA Skin Sciences, Inc. is a medical technology company that develops, commercializes, and markets innovative products for treating dermatologic conditions. The company's product portfolio includes the XTRAC® line of excimer lasers and VTRAC® lamp systems, which are used to treat psoriasis, vitiligo, and other skin conditions. Additionally, STRATA Skin Sciences offers the TheraClear® X Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The Pharos device is no longer available. The company was incorporated in New York in 1989 as Electro-Optical Sciences, Inc., reincorporated in Delaware in 1997, and changed its name to MELA Sciences, Inc. in April 2010. In June 2015, the company acquired the XTRAC® excimer laser and VTRAC® excimer lamp businesses from PhotoMedex, Inc. Prior to this acquisition, its sole product was the MelaFind® system, which aided dermatologists in evaluating atypical pigmented skin lesions. On January 5, 2016, the company changed its name to STRATA Skin Sciences, Inc. and discontinued the MelaFind business. In August 2021 and January 2022, the company acquired the Pharos U.S. dermatology business and the TheraClear acne treatment business, respectively. The Pharos line was discontinued concurrently with its acquisition, with service and support for Pharos laser system products provided through the expiration of extended warranty service contracts in 2024.

STRATA Skin Sciences, Inc. (OTC:SSKN) is a publicly traded company in the Healthcare sector. Wiseek has independently scored 2 items for SSKN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-03-26, rated 10/10. Across its 2 most recent items scored 7 or higher, the top rating is 10/10, with 2 rated 8 or above. Recent SEC coverage for SSKN spans 10-K, 8-K.

Recent high-impact activity:

  • STRATA Skin Sciences Faces Going Concern Doubt After Nasdaq Delisting, Debt Default, and Massive Tax Liabilities
  • STRATA Skin Sciences to be Delisted from Nasdaq, Plans to Go Dark

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$30.7M
Net Income
-$6.26M
Diluted EPS
-$1.35
Op. Cash Flow
-$2.79M
Free Cash Flow
-$4.26M
Gross Profit
$17.88M
Operating Income
-$4.7M
Cash & Equivalents
$7.91M
Total Debt
$15.35M
Debt / Equity
5.28×
Net Margin
-20.4%
Shares Outstanding
5.89M sh
Source: 10-K · filed 2026-03-26 · accession 0001140361-26-011231

Short Interest & Short Volume

7.07 days to cover

FINRA reported short interest of 58,986 shares in SSKN as of the September 15, 2026 settlement, unchanged from the prior period — about 7.1 days to cover at its recent average daily volume.

Short interest (bi-monthly positions)58,986 shares as of September 15, 2026
Change vs prior period 0.0%
Days to cover7.07 at avg daily volume of 8,346

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

No longer listed

SSKN (STRATA Skin Sciences, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed SSKN - Latest Insights

SSKN
Mar 25, 2026, 9:33 PM EDT
Filing Type: 10-K
Importance Score:
10
SSKN
Feb 11, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
10
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets